Bajaj Healthcare Q1 PAT +16% YoY to ₹13.7 Cr; margins expand after one-off Q4 loss

Bajaj Healthcare (standalone; the company files only standalone results, with Genrx not yet consolidated pending NCLT approval) posted Q1 FY27 revenue from operations of ₹165.63 Cr, up 11.3% YoY from ₹148.84 Cr and 8.2% QoQ from ₹153.06 Cr, with net profit for the period of ₹13.70 Cr versus ₹11.83 Cr a year ago — a clean +15.8% YoY with profit outpacing revenue. Because the YoY base (Q1 FY26) carried no exceptional items either, reported and adjusted YoY growth are the same ~15.8%; the eye-catching sequential swing (from a ₹22.85 Cr net loss in Q4 FY26 back to profit) is almost entirely the unwinding of a one-off — Q4 had absorbed a ₹33.25 Cr reversal of previously-booked Middle East technical know-how income — and should not be read as a fresh operating turnaround.

The quality of the print sits in the margins: EBITDA/operating margin widened to ~17.4% from 16.5% a year ago and net margin to 8.3% from 7.9%, even as cost of materials (₹91.59 Cr, ~55% of sales) rose with volume — indicating pricing/mix rather than input relief drove the gain. There are no formal street estimates or company guidance on record for this small-cap, so the result can't be benchmarked to consensus; management's only framing is the auditor's unmodified limited-review conclusion. Concurrent developments support the pharma-formulations/API base rather than move the needle yet: the SEC-CDSCO recommendation (Jun 2026) to manufacture/market anti-epileptic Cenobamate adds a pipeline product with no revenue in this quarter, and the board-approved sale of the Tarapur unit (up to ₹4.05 Cr) continues winding down the discontinued-operations drag, which narrowed to a ₹0.19 Cr loss this quarter from ₹0.34 Cr a year ago.

The stock went into the print at ₹386.55, up 21.9% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters.

Continuing-ops PAT ₹13.89 Cr — discontinued ops (units held for sale incl. Tarapur, board-approved divestment up to ₹4.05 Cr) trimmed to a ₹0.19 Cr loss.

Basic EPS ₹4.13 continuing / ₹4.07 total vs ₹3.85 YoY — cost of materials ₹91.59 Cr (~55% of sales), finance cost ₹6.09 Cr; limited review unmodified by Walker Chandiok & Co.